Maternal–fetal transport kinetics of carboplatin in the perfused human placental lobule:<i>In vitro</i>study

Al-Saleh, Eyad; Nandakumaran, Moorkath; Al-Rashdan, Ibrahim; Al-Harmi, Jehad; Al-Shammari, Majed

doi:10.1080/14767050701437302

Cited by 9 publications

(9 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few investigators presented clinical data, which describe the evidence of transplacental tranfer of platinum derivates (19,21). The transport from the mother to the fetal circulation was limited, even in concentrations exceeding the therapeutic level (3,22). There are clinical data on 36 patients who received platinum-based chemotherapy during their pregnancy, among them seven patients who had cervical cancer (11).…”

Section: Discussionmentioning

confidence: 96%

“…Life-saving therapy for the mother poses life-threatening concerns for the fetus. Neoadjuvant chemotherapy followed by radical hysterectomy has been revealed to be an option for women with invasive cervical carcinoma during pregnancy; however, there is limited data wih regard to the potential toxicity and teratogenicity (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18). Experimental data suggest that platinum derivates have a mutagenic and teratogenic potential.…”

mentioning

confidence: 98%

See 1 more Smart Citation

The therapeutic management of a twin pregnancy complicated by the presence of cervical cancer, following laparoscopic staging and chemotherapy, with an emphasis on cisplatin concentrations in the fetomaternal compartments amnion fluid, umbilical cord, and maternal serum

Marnitz

Schmittel

Bolbrinker

et al. 2009

Fertility and Sterility

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

mentioning

confidence: 98%

The therapeutic management of a twin pregnancy complicated by the presence of cervical cancer, following laparoscopic staging and chemotherapy, with an emphasis on cisplatin concentrations in the fetomaternal compartments amnion fluid, umbilical cord, and maternal serum

Marnitz

Schmittel

Bolbrinker

et al. 2009

Fertility and Sterility

View full text Add to dashboard Cite

“…To our knowledge, only three studies have reported placental transfer of platinum salt with the human placental perfusion model [ 75 , 78 , 79 ]. The only study on cisplatin placental transfer reported that cisplatin transport is negligible in the human placenta at term (13% of the value for antipyrine, the reference marker) [ 75 ].…”

Section: Resultsmentioning

confidence: 99%

“…The only study on cisplatin placental transfer reported that cisplatin transport is negligible in the human placenta at term (13% of the value for antipyrine, the reference marker) [ 75 ]. The same group used the human ex vivo model to assess placental transfer of carboplatin and found that the transport fraction also averaged 13% of the antipyrine transfer rate [ 78 ]. Thus, the authors suggested that there is minimal fetal risk when using cisplatin or carboplatin for pregnant patients.…”

Section: Resultsmentioning

confidence: 99%

Cancer during Pregnancy: A Review of Preclinical and Clinical Transplacental Transfer of Anticancer Agents

Benoit

Mir

Vialard

et al. 2021

Cancers

View full text Add to dashboard Cite

The occurrence of cancer during pregnancy is observed in 1 in 1000 pregnancies and is expected to increase given the trend of delaying childbearing. While breast cancer is the most common, the incidence of other cancers, such as cervical, ovarian, and lung cancers as well as hemopathies and melanomas, is also increasing. Thus, cancer occurrence in pregnant women raises questions of management during pregnancy and, especially, assessment of the treatment benefit–risk ratio to ensure optimal management for the mother while ensuring the safety of the fetus. Chemotherapy remains a cornerstone of cancer management. If the use of anticancer agents appears possible during pregnancy, while avoiding the first trimester, the extent of placental transfer of different anticancer agents varies considerably thereafter. Furthermore, the significant physiological pharmacokinetic variations observed in pregnant women may have an impact on the placental transfer of anticancer agents. Given the complexity of predicting placental transfer of anticancer agents, preclinical studies are therefore mandatory. The aim of this review was to provide updated data on in vivo and ex vivo transplacental transfer of anticancer agents used in the management of the most common pregnancy-associated cancers to better manage these highly complex cases.

show abstract

“…55 Maternalfetal transport kinetics of carboplatin were studied ex vivo on perfused human placental lobules. 56 In that study, the transport of carboplatin from the maternal circulation to the fetal circulation was limited in the human placenta at term, even for concentrations of carboplatin exceeding twice the therapeutic concentrations. However, we discovered contradictory results in the current review: either detectable levels of cisplatin or platinum-DNA adducts were identified in 4 neonates who were exposed in utero to cisplatin and carboplatin, suggesting a late transplacental transfer of these drugs (Table 3).…”

Section: Transplacental Transfer Of Cisplatin and Carboplatinmentioning

confidence: 99%

Use of platinum derivatives during pregnancy

Mir

Berveiller

Ropert

et al. 2008

Cancer

119

View full text Add to dashboard Cite

The incidence of cancer during pregnancy is increasing given the trend for women to postpone childbearing. Knowledge of the potential toxicity and teratogenicity of chemotherapy agents is crucial for patient counseling. Platinum derivatives are active against various malignancies that occur more frequently during pregnancy: melanoma, cervical and ovarian cancers, and lung cancer. The authors of this article performed a systematic review of reports documenting the use of platinum derivatives during pregnancy in the English literature from 1977 through January 2008. Forty-three pregnancies were described: 36 patients received cisplatin, 6 patients received carboplatin, and 1 patient received both drugs. Two fetal malformations occurred after in utero exposure to cisplatin, but the causative link between cisplatin administration and these malformations remains speculative. However, either detectable cisplatin levels or platinum-DNA adducts were observed in neonates who were exposed to platinum derivatives during the third trimester, providing evidence for a late-onset transplacental transfer of these drugs. The administration of platinum derivatives, although feasible during the second and third trimesters of pregnancy, raises concern regarding the transplacental transfer of these drugs in late pregnancy and has unknown short-and long-term effects.

show abstract

Maternal–fetal transport kinetics of carboplatin in the perfused human placental lobule:In vitrostudy

Cited by 9 publications

References 36 publications

The therapeutic management of a twin pregnancy complicated by the presence of cervical cancer, following laparoscopic staging and chemotherapy, with an emphasis on cisplatin concentrations in the fetomaternal compartments amnion fluid, umbilical cord, and maternal serum

The therapeutic management of a twin pregnancy complicated by the presence of cervical cancer, following laparoscopic staging and chemotherapy, with an emphasis on cisplatin concentrations in the fetomaternal compartments amnion fluid, umbilical cord, and maternal serum

Cancer during Pregnancy: A Review of Preclinical and Clinical Transplacental Transfer of Anticancer Agents

Use of platinum derivatives during pregnancy

Contact Info

Product

Resources

About